
News|Articles|April 19, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of April 19, 2022
Author(s)Sydney Jennings
Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.
Advertisement
How many fully vaccinated Americans have received a booster dose?
According to the Centers for Disease Control and Prevention (CDC) as of today, April 19, 2022, at 5:16 PM, EDT:
45.5% of fully vaccinated persons in the US have received a booster dose of COVID-19 vaccine.
What percentage of people across age groups in the US have been fully vaccinated?
• 66% of total US population
• 70.1% of US population aged ≥5 years
• 74.4% of US population aged ≥12 years
• 75.9% of US population aged ≥18 years
• 89.8% of US population aged ≥65 years
How many cases of COVID-19 have been confirmed in the US?
According to the Johns Hopkins COVID-19 interactive map , as of today, April 19, 2022 at 4:21 PM, EDT, there have been:
• 80 710 329 confirmed cases and
• 989 265 deaths
• 989 265 deaths
In the past 28 days, the 3 states with the most new cases are:
1. New York: 120 814
2. Texas: 98 428
3. California:83 023
2. Texas: 98 428
3. California:83 023
Deaths: California has the highest number of deaths due to COVID-19 with 89 784 reported fatalities, followed by Texas with 87 892 and Florida with 73 738.
How many cases of COVID-19 have been confirmed globally?
Globally, there have been 505 473 996 confirmed cases, 6 202 109 deaths, and 11 190 876 641 vaccine doses administered.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
Investigational Two-Drug HIV Regimen Shows Minimal Impact on Weight and Lipids in Phase 3 Trials
2
Lilly's Novel Oral GLP-1 Orforglipron Shows Superior Efficacy in 2 Phase 3 Trials
3
The Menopause Society 2025 Annual Meeting: A Primary Care Preview
4
Three GLP-1 Receptor Agonists Show Comparable Cardiorenal Protection in Large US Cohort with T2D
5